Anticoagulation for mechanical heart valves: A role for patient based therapy

Journal of Thrombosis and Thrombolysis

Volumn 25, Issue 1, 2008, Pages 18-25

  Emery, Robert W ^a   Emery, Ann M ^a   Raikar, Goya V ^a   Shake, Jay G ^a  

^a REGIONS HOSPITAL   (United States)

Author keywords

Anticoagulant related hemorrhage; Anticoagulation; Mechanical heart valves; Thromboembolism; Valvere placement surgery

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; WARFARIN;

ANTICOAGULANT THERAPY; AORTA VALVE THROMBOSIS; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HUMAN; LONG TERM CARE; MITRAL VALVE THROMBOSIS; MONOTHERAPY; PATHOLOGICAL ANATOMY; PATIENT EDUCATION; PRIORITY JOURNAL; PROSTHESIS FAILURE; RISK FACTOR; RISK MANAGEMENT; THROMBOEMBOLISM; TRICUSPID VALVE THROMBOSIS; VALVULAR HEART DISEASE;

ANTICOAGULANTS; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; RISK FACTORS; THROMBOEMBOLISM;

EID: 38049116013     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0105-x     Document Type: Conference Paper

References (44)

1. Cannegieter SC, Rosendaal FR, Briet E (1994) Thromboembolic and bleeding complications in patients with mechanical heart valves prostheses. Circulation 89:635-641
2. Joyce LD, Emery RW, Nicoloff DM (1978) Ball variance and fracture of mitral valve prosthesis causing recurrent thromboemboli. J Thorac Cardiovasc Surg 75:309-312
3. Emery RW, Lindsay WG, Anderson RW, Jorgensen CR, Wang Y, Nicoloff DM (1979) Clinical and hemodynamic results with the St. Jude Medical aortic valve prosthesis. Surg Forum 30:235-238
4. Potter DD, Sundt TM, Zehr KJ et al (2005) Operative risk of reoperative aortic valve replacement. J Thorac Cardiovasc Surg 129:94-103
5. Jamison WRE, Burr LH, Migagishima RT et al (2003) Re-operation for bioprosthetic mitral structure failure: Risk assessment. Circulation 108(Suppl II):II-98-II-102
6. Emery RW, Krogh CC, Arom KV et al (2005) The St. Jude Medical cardiac valve prosthesis: A 25-year experience with single valve replacement. Ann Thorac Surg 79:776-783
7. Grunkemeier GL, Wu YX (2003) "Our complication rates are lower than theirs": Statistical critique of heart valve comparisons. J Thorac Cardiovasc Surg 125:290-300
8. Koertke H, Koertke R (2001) International standardized ratio self-management after mechanical valve replacement: Is an early start advantageous. Ann Thorac Surg 72:44-48
9. Bonow RO, Carabello BA, Chatterjee K et al (2006) ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 48:1-148
10. Buchart EG, Gohlke-Barwolfe C, Antunes MJ et al (2005) Recommendations for the improvement of patients after heart valve surgery. Eur Heart J 26:2463-2471
11. Cannegieter SC, Rosendaal FR, Wintzen AR et al (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333:11-17
12. Salem DN, Stein PD, Al-Ahmed A et al (2004) Antithrombotic therapy in valvular heart disease - native and prosthetic: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:4575-4825
13. Khan S, Tronto A, DeRobertis M et al (2001) Twenty-year comparison of tissue and mechanical valve replacement. J Thorac Cardiovasc Surg 122:257-269
14. Ikonomides JS, Krantz JM, Crumblely AT et al (2003) Twenty-year experience with the St. Jude Medical valve prosthesis. J Thorac Cardiovasc Surg 126:2022-2031
15. Buchart EG, Ionesco A, Payne N, Grobings T, Grunkemeier GL, Fraser AG (2003) A new scoring system to determine thromboembolic risk after heart valve replacement. Circulation 108(Suppl II):II-68-2-74
16. Buchart EG, Lewis PA, Bethel JA et al (1991) Adjusting anticoagulation to prosthesis thrombogenicity and patient risk factors. Circulation 84(Suppl III):61-69
17. Buchart EG, Moreno de la Santa P, Rooney ST et al (1995) Arterial risk factors in cerebrovascular events following aortic valve replacement. J Heart Valve Dis 4:1-8
18. Levine MN, Raskob G, Beyth RJ, Kearen C, Schulman S (2004) Hemorrhagic complications of anticoagulant treatment. Chest 126:2875-3105
19. Horstkette D, Schulte H, Bircks W et al (1993) Unsuspected findings concerning thromboembolic complications and anticoagulation after complete 10 year follow-up of patients with St. Jude Medical prosthesis. J Heart Valve Dis 2:291-301
20. Koertke H, Minari K, Boethig D et al (2003) INR self management permits lower anticoagulant levels after mechanical heart valve replacement. Circulation 108(Suppl II):75-78
21. Buchart EG, Payne N, Li HH et al (2002) Better anticoagulation control improves survival after valve replacement. J Thorac Cardiovasc Surg 123:715-723
22. Koertke H, Ziherman A, Wagner O, Koerfer R (2007) Self-management of oral anticoagulant improves long-term survival in patients with mechanical heart valve replacement. Ann Thorac Surg 83:24-29
23. Emery RW, Erickson CA, Arom KV et al (2003) Replacement of the aortic valve in patients under 50 years of age: Long term follow-up of the St. Jude Medical prosthesis. Ann Thorac Surg 75:1815-1819
24. Emery RW, Nicoloff DM (1979) St. Jude Medical cardiac valve prosthesis: in vitro studies. J Thorac Cardiovasc Surg 78:269-276
25. Becker RC, Eisenberg P, Turpie AG (2001) Pathobiologic features and prevention of thrombotic complications associated with prosthetic heart valves: Fundamental principles and the contribution of platelets and thrombin. Am Heart J 141:1025-1035
26. Bluestein D, Rambod E, Gharib M (2000) Vortex shearing as a mechanism for free emboli formation in mechanical heart valves. J Biomech Eng 122:125-134
27. Garcia-Rinaldi R (2004) Clopidogrel - ASA combination inhibits the thrombogenicity of St. Jude Medical mechanical aortic prosthesis. CTS Net Report, September
28. Turpie AG, Gent M, Larpacis A et al (1993) A comparison of aspirin with placeron patients treated with warfarin after heart valve replacement. N Engl J Med 329:524-525
29. Hartz RS, LaCicero J, Kucich V et al (1986) Comparative study of warfarin versus anti-platelet therapy in patients with a St. Jude Medical valve in the aortic position. J Thorac Cardiovasc Surg 92:684-690
30. Schlitt A, Von Bardelesen RS, Ehrlich A et al (2003) Clopidogrel and ASA in the prevention of thromboembolic complications after mechanical aortic heart valve replacement. Thromb Res 109:131-135
31. Czer LSC, Matloff JM, Chaux A, DeReberds RN, Gray RJ (1987) Comparative clinical experience with porcine bioprosthetic and St. Jude valve replacement. Chest 91:503-514
32. Rebeiro PA, Al-Zaibag M, Idris M et al (1986) Anti-platelet drugs and the incidence of thromboembolic complications of the St. Jude Medical aortic prosthesis in patients with pneumatic heart disease. J Thorac Cardiovasc Surg 92:684-690
33. Fuster V, Rydea LT, Cannon DS et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary. Circulation 114:700-752
34. Massel D, Little SH (2001) Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: A meta-analysis. J Am Coll Cardiol 37:869-878
35. Carrier M, Hebert Y, Pellerin M et al (2003) Tricuspid valve replacement: An analysis of 25 years of experience at a single center. Ann Thorac Surg 75:47-50
36. Kang CH, Ahn H, Kim KH, Kim KB (2005) Long-term result of 1144 carbomedics mechanical valve implants. Ann Thorac Surg 79:1939-1944
37. Filsoufi F, Anyanwu AC, Salzberg SP et al (2005) Long-term outcomes of tricuspid valve replacement in the modern era. Ann Thorac Surg 80:845-850
38. Buchart EG, Moreno de la Santa P, Rooney ST, Lewis SA (1994) The role of risk factors and trigger factors in cerebrovascular events after mitral valve replacement: Implication for antithrombotic management. J Card Surg 9(Suppl):2278-2286
39. Rizzoli G, Vendramin I, Nesseris G et al (2004) Biological or mechanical prosthesis in tricuspid position? A meta-analysis of intra-institutional results. Ann Thorac Surg 77:1107-1614
40. Menendez-Jandula B, Souto JC, Oliver J et al (2005) Comparing self-management of oral anticoagulation with clinic management. Ann Intern Med 142:1-10
41. Sidhu P, O'Kane HO (2001) Self-managed anticoagulation: Results from a two-year prospective randomized trial with heart valve patients. Ann Thorac Surg 72:1523-1527
42. Arom KV, Nicoloff DM, Kersten TE et al (1989) Ten year follow-up study of patients who had double valve replacement with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 98:1008-1016
43. Meschengieser SS, Fondevila CG, Frontroth J, Sandarelli MT, Lazzari MA (1997) Low-intensity oral anti-coagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: A randomized trial in patients with mechanical heart valves. J Thorac Cardiovasc Surg 113:910-916
44. Hirsh J, Salzman EW, Harker L et al (1989) Aspirin and other anti-platelet active drugs: Relationship among dose, effectiveness and side effects. Chest 95:512-518